Search | Clinical Trials Finder

Conditions: Leukemia
Interventions: Venetoclax, Standard Chemotherapy; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more

Conditions: Dry Eye
Interventions: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Town and Country, Missouri

Conditions: Advanced Squamous Tumors
Interventions: ABBV-711, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Chicago, Illinois + 3 more

Conditions: Progressive Supranuclear Palsy (PSP)
Interventions: ABBV-8E12; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: La Jolla, California • Dallas, Texas

Conditions: Psoriatic Arthritis
Interventions: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more

Conditions: Healthy
Interventions: RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer, Cancer
Interventions: Venetoclax, Capecitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: Myelofibrosis (MF)
Interventions: ABBV-744, Navitoclax, Ruxolitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Glendale, California • Orlando, Florida • Grayslake, Illinois + 4 more

Conditions: Multiple Myeloma
Interventions: Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 109
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more

Conditions: Pain
Interventions: Hydrocodone/Acetaminophen Extended Release, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Pasadena, California • Austin, Texas • Salt Lake City, Utah

Conditions: Giant Cell Arteritis (GCA)
Interventions: Upadacitinib, Corticosteroid (CS), Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 53
States / cities: Huntsville, Alabama • Glendale, Arizona • Long Beach, California + 46 more

Conditions: Advanced Parkinson's Disease
Interventions: Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 8
States / cities: Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more

Conditions: Upper Limb Essential Tremor
Interventions: AGN-151607-DP, Placebo for AGN-151607-DP; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 18
States / cities: Carlsbad, California • Fresno, California • Fullerton, California + 15 more

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Conditions: Non-Small Cell Lung Cancer, c-MET
Interventions: Telisotuzumab Vedotin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Chandler, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Interventions: Dasatinib, Methotrexate, Prednisone, Rituximab, Venetoclax, Blinatumomab, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Schizophrenia
Interventions: Placebo, Emraclidine 10 mg, Emraclidine 30 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 42
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 35 more

Conditions: Ulcerative Colitis (UC)
Interventions: Upadacitinib (ABT-494), Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 147
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more

Conditions: Acute Myeloid Leukemia
Interventions: Cytarabine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Venetoclax, Azacitidine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 9
States / cities: Duarte, California • Palo Alto, California • Sacramento, California + 4 more

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Conditions: Juvenile Idiopathic Arthritis, JIA
Interventions: adalimumab, Methotrexate; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more

Search by objective public record fields.

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

RTA 408 Lotion in Healthy Volunteers

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Acute Pain Study Following Bunionectomy

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Juvenile Idiopathic Arthritis (JIA) Registry